Etoricoxib: Clinical Overview
Etoricoxib is a highly selective COX-2 inhibitor indicated for osteoarthritis (60 mg daily), rheumatoid arthritis (90 mg daily), and acute gouty arthritis (120 mg daily), with demonstrated efficacy comparable to traditional NSAIDs but requiring careful cardiovascular risk assessment before use. 1, 2
Indications
Etoricoxib is approved for:
- Osteoarthritis: 60 mg once daily
- Rheumatoid arthritis: 90 mg once daily
- Acute gouty arthritis: 120 mg once daily
- Chronic non-bacterial osteitis (CNO): 90 mg daily (or temporarily 120 mg/day) 3
- Acute pain conditions (in select jurisdictions): 120 mg once daily
The drug has Level A evidence supporting its efficacy in acute gout, making it the only COX-2 inhibitor specifically approved for this indication 4. For gout specifically, etoricoxib 120 mg demonstrated superior efficacy to indomethacin in randomized controlled trials 4, 5.
Contraindications
Absolute contraindications include:
- Active cardiovascular disease (ischemic heart disease, stroke)
- Uncontrolled hypertension 6
- History of CABG surgery (within 10-14 days) 7
- Active peptic ulcer disease or gastrointestinal bleeding
- Severe hepatic impairment
- Severe renal impairment (creatinine clearance <30 mL/min)
- Pregnancy (third trimester) 7
- Known hypersensitivity to COX-2 inhibitors or aspirin-induced asthma
Important caveat: The NICE osteoarthritis guidelines specifically recommend against using etoricoxib 60 mg as a first-choice COX-2 inhibitor, suggesting other COX-2 inhibitors or standard NSAIDs instead 8. This reflects concerns about the cardiovascular risk-benefit profile at this dose.
Dosing Recommendations
Standard Dosing
- Osteoarthritis: 60 mg once daily (lowest effective dose)
- Rheumatoid arthritis: 90 mg once daily
- Acute gout: 120 mg once daily (duration until attack resolves, typically 8 days)
- Chronic musculoskeletal pain: 60 mg once daily
Key Dosing Principles
Use the lowest effective dose for the shortest duration possible 8, 7. The drug's 22-hour half-life supports once-daily dosing 9, 10. Steady-state concentrations are achieved after 7 days of daily administration, with an accumulation ratio of 2.1 10.
Dose Adjustments
- Renal impairment: Use with caution; contraindicated if CrCl <30 mL/min
- Hepatic impairment: Use with caution; contraindicated in severe disease
- Elderly patients: No specific dose adjustment required, but increased monitoring necessary due to higher cardiovascular and renal risks 8, 7
Administration with Food
Etoricoxib can be taken without regard to meals 10. A high-fat meal decreases the rate of absorption (delays Tmax by approximately 2 hours) but does not affect the extent of absorption (AUC remains unchanged). The absolute bioavailability is essentially 100% 10. Peak concentrations (Cmax) occur 4-5 hours after administration under fasted conditions 7.
Monitoring Guidelines
Baseline Assessment
Before initiating etoricoxib, assess:
- Cardiovascular risk factors: History of MI, stroke, hypertension, heart failure, peripheral arterial disease
- Gastrointestinal risk: Prior ulcer disease, GI bleeding, concurrent anticoagulant/corticosteroid use, age >65 years
- Renal function: Baseline creatinine clearance
- Hepatic function: Baseline liver enzymes
- Blood pressure: Document baseline 8, 7
Ongoing Monitoring
Monitor the following parameters regularly 8, 7:
- Blood pressure: Check within 2 weeks of initiation and periodically thereafter. Etoricoxib increases hypertension risk more than some comparator NSAIDs 11, 6
- Renal function: Monitor creatinine and electrolytes, especially in elderly patients, those with pre-existing renal disease, heart failure, or concurrent diuretic use
- Hepatic function: Periodic liver enzyme monitoring, particularly in the first months of therapy
- Cardiovascular symptoms: Remain alert for chest pain, shortness of breath, weakness, or slurred speech 7
- Gastrointestinal symptoms: Monitor for abdominal pain, black stools, or signs of bleeding 7
- Edema/fluid retention: Assess for lower extremity swelling 9
Treatment Response Evaluation
For chronic conditions like osteoarthritis, re-evaluate efficacy and necessity of continued treatment at 12 weeks 8. If insufficient response or if pain is controlled, consider tapering or discontinuation.
Safety Considerations
Cardiovascular Risk
All COX-2 inhibitors, including etoricoxib, carry increased cardiovascular thrombotic risk 11, 7. The MEDAL program showed etoricoxib had similar cardiovascular event rates to diclofenac (HR 1.02,95% CI 0.87-1.18), but both drugs are on the more COX-2-selective end of the spectrum and carry higher risk than less selective NSAIDs 11. Patients with known cardiovascular disease or multiple risk factors are at greatest risk 7.
Gastrointestinal Safety
Etoricoxib demonstrates approximately 50% reduction in upper GI perforations, ulcers, and bleeds compared to non-selective NSAIDs 9, 6. However, always co-prescribe a proton pump inhibitor when using etoricoxib in patients with GI risk factors 8. Risk factors include: age >65, prior ulcer disease, concurrent corticosteroids, anticoagulants, or aspirin use.
Critical warning: Patients with gastric or gastroesophageal tumors are at increased risk for hemorrhage with etoricoxib and should avoid this drug 12.
Renal and Hepatic Effects
Like all NSAIDs, etoricoxib can cause fluid retention, edema, and hypertension through renal prostaglandin inhibition 7, 9. Monitor for signs of renal impairment, particularly in at-risk populations (elderly, heart failure, cirrhosis, volume depletion).
Drug Interactions
- Aspirin: Concurrent use increases GI bleeding risk without clear cardiovascular benefit 8, 11, 13. Consider alternative analgesics before adding etoricoxib to aspirin therapy 8
- Anticoagulants: Significantly increases bleeding risk (RR 5.6 when combined with NSAIDs) 13
- Antihypertensives: May reduce efficacy of blood pressure medications 7
Clinical Context and Practical Considerations
For osteoarthritis, etoricoxib should be reserved for patients who have failed paracetamol and topical NSAIDs, and who have low cardiovascular risk but significant GI risk factors 8. The NICE guidelines place oral NSAIDs/COX-2 inhibitors in the outer treatment circle, indicating they should be used only after core treatments (exercise, weight loss) and second-line options have been attempted.
For acute gout, etoricoxib 120 mg is highly effective (NNT 1.5-1.9 for 50% pain relief) and represents a valid first-line option alongside NSAIDs, colchicine, and corticosteroids 4, 14, 15. The choice depends on patient comorbidities and contraindications to other agents.
Common pitfall: Prescribing etoricoxib without adequate cardiovascular risk stratification. Always document why the benefits outweigh cardiovascular risks, particularly in patients with hypertension, diabetes, or hyperlipidemia.